Abstract
Backgrounds: Drug coated balloons (DCBs) are new on stented-based anti-proliferative drug delivery systems, recently introduced in interventional cardiology. Their primary aim is to transfer an anti-proliferative drug to reduce the subsequent neo-intima hyperplasia and to maintain the normal vessel diameter and function.
Methods: A review of the most recent influential studies about DCBs in all the fields of interventional cardiology has been performed.
Results: As demonstrated by different studies, DCBs have different theoretical advantages over Drug Eluting Stents (DESs), especially for the treatment of some endovascular lesions, as In-Stent Restenosis (ISR), coronary bifurcations, small vessels disease and peripheral artery disease at femoropopliteal and below the knee sites.
Conclusion: Despite the need of further studies are needed to elucidate the optimal use of DCBs their current use in interventional cardiology appears promising.
Keywords: Balloon, angioplasty, drug, interventional, anti-proliferative drug delivery, Drug Coated Balloons (DCBs).
Current Pharmaceutical Design
Title:Drug-Coated Balloons Applications in Interventional Cardiology
Volume: 24 Issue: 4
Author(s): Gianluca Rigatelli*Marco Zuin
Affiliation:
- Section of Cardiovascular Diagnosis and Endoluminal Interventions, Rovigo General Hospital, Rovigo,Italy
Keywords: Balloon, angioplasty, drug, interventional, anti-proliferative drug delivery, Drug Coated Balloons (DCBs).
Abstract: Backgrounds: Drug coated balloons (DCBs) are new on stented-based anti-proliferative drug delivery systems, recently introduced in interventional cardiology. Their primary aim is to transfer an anti-proliferative drug to reduce the subsequent neo-intima hyperplasia and to maintain the normal vessel diameter and function.
Methods: A review of the most recent influential studies about DCBs in all the fields of interventional cardiology has been performed.
Results: As demonstrated by different studies, DCBs have different theoretical advantages over Drug Eluting Stents (DESs), especially for the treatment of some endovascular lesions, as In-Stent Restenosis (ISR), coronary bifurcations, small vessels disease and peripheral artery disease at femoropopliteal and below the knee sites.
Conclusion: Despite the need of further studies are needed to elucidate the optimal use of DCBs their current use in interventional cardiology appears promising.
Export Options
About this article
Cite this article as:
Rigatelli Gianluca *, Zuin Marco , Drug-Coated Balloons Applications in Interventional Cardiology, Current Pharmaceutical Design 2018; 24 (4) . https://dx.doi.org/10.2174/1381612824666171227212112
DOI https://dx.doi.org/10.2174/1381612824666171227212112 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Control of Male Sexual Responses
Current Pharmaceutical Design Specific Nutritional Needs for Children. Are Children Small Adults?
Current Nutrition & Food Science Telomeres, Senescence and Longevity: The Role of Oxidative Stress and Antioxidants
Current Pharmacogenomics Perioperative Thromboprophylaxis and Anticoagulation in Patients Undergoing Non-Cardiac Vascular Surgery
Current Vascular Pharmacology Hypotensive Effects of the Triterpene Oleanolic Acid for Cardiovascular Prevention
Current Molecular Pharmacology The Journey of the Non-Vascular Relief for Migraine: From ‘Triptans’ To ‘Ditans’
Current Clinical Pharmacology Role of Asymmetric Dimethylarginine in Cardiorenal Syndrome
Current Pharmaceutical Design Pharmacokinetics-Pharmacology Disconnection of Herbal Medicines and its Potential Solutions with Cellular Pharmacokinetic-Pharmacodynamic Strategy
Current Drug Metabolism Therapeutic Development of Interrelated Metabolic and Neurodegenerative Disorders
Current Pharmaceutical Design Is there a Teratogenicity Risk Associated with Cannabis and Synthetic Cannabimimetics’ (‘Spice’) Intake?
CNS & Neurological Disorders - Drug Targets The Role of microRNAs in the Development of Type 2 Diabetes Complications
Current Pharmaceutical Design The First Approved Agent in the Glitazar’s Class: Saroglitazar
Current Drug Targets May Oxygen-Ozone Therapy Improves Cardiovascular Disorders?
Cardiovascular & Hematological Disorders-Drug Targets Mid-Aortic Syndrome: A Rare Cause of Renovascular Hypertension in Childhood Treated Percutaneously with an Unusual Vascular Access
Current Pediatric Reviews Oxidative Stress in Essential Hypertension
Current Pharmaceutical Design Inflammation, Oxidative Stress and Metabolic Syndrome: Dietary Modulation
Current Vascular Pharmacology Radionuclide PET and PET/CT in Coronary Artery Disease
Current Pharmaceutical Design Reactive Oxygen Species and Antioxidants in the Pathophysiology of Cardiovascular Disease: Does the Actual Knowledge Justify a Clinical Approach?
Current Vascular Pharmacology Novel Risk Factors Related to Stable Angina
Current Pharmaceutical Design Lipoprotein (a) and Cardiovascular Risk: The Show Must go on
Current Medicinal Chemistry